Effects of Meal Macronutrients on Postprandial Lipids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-03

Study Completion Date

2031-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome.

Objective:

To learn more about how different types of foods affect fat levels in the blood.

Eligibility:

People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed.

Design:

Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal.

Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after.

Participants will have other tests during their stays:

* A resting metabolic test captures the air they exhale and measures how much energy they use at rest.
* A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have.
* A Fibroscan is a special type of ultrasound of the liver.
* A body surface scan uses lasers to measure the total area of the body.
* A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body.

Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dietary Treatment Study of Fat Synthesis and Risk of Cardiovascular Disease

NCT02075710

Overweight and Obesity

UNKNOWN NA

The Effect of Meal Composition on Blood Lipids

NCT02529709

Dyslipidemia

COMPLETED NA

Macronutrients and Postprandial Vascular Function

NCT03139890

Dietary Fats Carbohydrates Proteins +3 more

COMPLETED NA

Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes

NCT00608049

Overweight Cardiovascular Diseases

COMPLETED NA

Elucidation and Monitoring Postprandial Endothelial Function

NCT00766623

Cardiovascular Disease Endothelial Dysfunction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

This is a single site, randomized cross-over study assessing the effects of different test meals of varying macronutrient composition on post-prandial lipid metabolism. Studies will be conducted in healthy individuals and in several patient populations including those with nephrotic syndrome (NS), lipodystrophy, and metabolic syndrome.

The study hypothesis is that the number, composition and kinetics of lipid-containing particles will differ in the post-prandial state:

1. Within subjects, comparing meals of differing macronutrient composition (i.e. high fat versus high carbohydrate)
2. Between subjects with different disorders (i.e., lipodystrophy vs. NS vs. healthy)
3. Within subjects before and after treatment of their underlying disorders (i.e. nephrotic vs non-nephrotic states)

Objectives:

* Primary Objective: Determine the difference in postprandial triglycerides between meals of different macronutrient composition within each study cohort.
* Secondary Objective: Determine differences in post-prandial triglycerides between different study populations.

Endpoints:

* Primary Endpoint: Difference in baseline adjusted AUC for TG for 8 hours after meals of different macronutrient composition.
* Secondary Endpoints: Difference in baseline adjusted AUC for TG for each meal test between study cohorts

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrotic Syndrome Lipodystrophy Metabolic Syndrome Healthy Volunteer Diabetes Metabolic Associated Steatotic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Group Type EXPERIMENTAL

High carb then high fat breakfast

Intervention Type OTHER

High carb then high fat breakfast

High fat then high carb breakfast

Intervention Type OTHER

High fat then high carb breakfast

Lipodystrophy

Group Type EXPERIMENTAL

High carb then high fat breakfast

Intervention Type OTHER

High carb then high fat breakfast

High fat then high carb breakfast

Intervention Type OTHER

High fat then high carb breakfast

Metabolic syndrome

Group Type EXPERIMENTAL

High carb then high fat breakfast

Intervention Type OTHER

High carb then high fat breakfast

High fat then high carb breakfast

Intervention Type OTHER

High fat then high carb breakfast

Nephrotic syndrome

Group Type EXPERIMENTAL

High carb then high fat breakfast

Intervention Type OTHER

High carb then high fat breakfast

High fat then high carb breakfast

Intervention Type OTHER

High fat then high carb breakfast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High carb then high fat breakfast

Intervention Type OTHER

High fat then high carb breakfast

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Age \>= 18 years
2. Average alcohol intake in the past 6 months \< 30 g/day (male) or \<20 g/day (female)

1. In good general health with no known active medical conditions as evidenced by medical history
2. Fasting glucose \<100 mg/dL
3. HbA1c \<5.7%
4. Fasting triglycerides \<150 mg/dL
5. ALT and AST within normal limits
6. BMI \>=18.5 to \<25 kg/m\^2 (or \<23 kg/m\^2 in participants of Asian descent)
7. Not taking any medications or supplements that, in the opinion of the investigator, would interfere with interpretation of study data.

1\. Obesity defined as either

1. BMI \>30 kg/m\^2 (or \>=27 kg/m\^2 in participants of Asian descent), OR
2. Elevated waist circumference as defined below:

* Country/Ethnic group - Europid, Sub-Saharan African, Eastern Mediterranean and Middle East (Arab):

--Sex: Male - Waist circumference: \>=94cm

--Sex: Female - Waist circumference: \>=80cm
* Country/Ethnic group - South Asian, Chinese, Japanese, Ethnic South and Central American:

* Sex: Male - Waist circumference: \>=90cm
* Sex: Female - Waist circumference: \>=80cm

2\. Elevated triglycerides defined as EITHER

2a. Fasting triglycerides \>= 150 mg/dL at screening, OR

2b. Specific treatment for hypertriglyceridemia

3\. Low HDL cholesterol, defined as EITHER

3a. HDL \<40 mg/dL (males) or \<50 mg/dL (females) at screening, OR

3b. Specific treatment for low HDL

4\. Elevated blood pressure defined as EITHER

4a. Systolic BP \>= 130 at screening, OR

4b. Diastolic BP \>= 85 mm Hg at screening, OR

4c. Treatment of previously diagnosed hypertension

5\. Elevated glucose defined as EITHER

5a. HbA1c \>= 5.7% (at screening), OR

5b. Fasting serum glucose \>= 100 mg/dL (at screening), OR

5c. 2-hour post-load glucose levels \>= 140 mg/dL (by history), OR

5d. Prior diagnosis of type 2 diabetes

1. Clinical diagnosis of generalized or partial lipodystrophy based on reduction in adipose tissue outside the normal range in some or all adipose depots (including, at aminimum, the gluteofemoral depot).
2. Insulin resistance as defined by fasting insulin \>22.5 or high exogenous insulin requirement (\> 2 units per kg per day or \> 200 units total per day) at screening.

1. History of biopsy proven non-diabetic glomerular disease (any histology)
2. Nephrotic range proteinuria defined by ANY of the following:

2a. Protein/creatinine ratio uPCR \>= 3.5 g/g at screening, OR

2b. 24 hour protein excretion \>= 3.5 gr/24hr) at screening, OR

2c. History of nephrotic range proteinuria (as defined above) within the past 5 years but in complete (defined as proteinuria \<= 0.3 g/day or partial remission (defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria \< 3.5 g/day) based on 24 hr urine or uPCR at time of screening

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
1. Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, paleo or Atkins diets, among others).
2. Plans to actively gain or lose weight during the study period (other than changes in water balance as clinically needed in subjects with nephrotic syndrome).
3. Change in body weight of \>5% or \>3 kg (whichever is larger) in the 3 months prior to screening (by participant report) in participants who do NOT have nephrotic syndrome.
4. Body weight \>450 lbs (upper limit that can be accommodated by DXA scanner).
5. Participating in a regular strenuous exercise program (\> 2h/week of vigorous activity) as determined by volunteer report or evidence of vigorous exercising in order to lose weight, change body shape, or to counteract the effects of eating.
6. Uncontrolled diabetes, defined as HbA1c \>9% at screening.
7. Lipemia defined as fasting or non-fasting triglycerides of \>1000 mg/dL at screening.
8. Renal dysfunction defined as eGFR \<50 mL/min/1.73 m\^2 at screening.
9. In participants with liver disease, history of decompensated advanced liver disease, defined as direct bilirubin \> 0.5 g/dL, PT \> 18 seconds, albumin \< 3 g/dL, MELD score \> 12, or history of ascites, encephalopathy, variceal bleeding, spontaneous bacterial

peritonitis or liver transplant.
10. History of hypertriglyceridemia-induced pancreatitis within 3 months prior to screening.
11. Positive pregnancy test or breastfeeding at screening.
12. Clinically significant abnormalities in thyroid function, blood counts, as assessed by screening labs.
13. Acute cardiovascular events within the past 6 months
14. Anemia (Hgb \<10 mg/dL in women or \<12 mg/dL in men) at screening
15. Food allergies or other dietary restrictions that could increase risk associated with test meals or cause the subject to be unwilling to consume test meals (i.e. celiac disease, vegan diets).
16. Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.
17. Subjects treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks prior to screening.
18. Blood donation in the last 2 weeks or planned blood donation during the study
19. Subjects requiring regular transfusions for any reason.
20. Subjects with known gastroparesis
21. Inability to adhere to Lifestyle Considerations throughout study duration.
22. Inability of the subject to understand and the unwillingness to sign a written informed consent document.
23. Unwillingness to comply with all study procedures and unavailable for the duration of the study
24. Any other condition or medication which, in the opinion of the investigator, increases risk to the subject, prevents the subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No